magazinelogo

International Journal of Clinical and Experimental Medicine Research

ISSN Online: 2575-7970 ISSN Print: 2575-7989 CODEN: IJCEMH
Frequency: bimonthly Email: ijcemr@hillpublisher.com
Total View: 3192325 Downloads: 712209 Citations: 301 (From Dimensions)
ArticleOpen Access http://dx.doi.org/10.26855/ijcemr.2022.07.002

Formulation and Evaluation of Orodispersible Tablets of Etoricoxib Using Hibiscus Rosa Sinesis Muscillage as Natural Super Disintegrant

Sandeep Patel, Komal Tikariya*, Jayanti Mukherjee

Department of Pharmaceutics, Shri Bherulal Pharmacy Institute, Indore (M.P), India.

*Corresponding author: Komal Tikariya

Published: May 13, 2022

Abstract

The aim of the study is to formulate orodispersible tablet of Etoricoxib for the pain management of rheumatoid arthritis and to improve the efficacy and patient compliance. In the present work, orodispersible tablets of Etoricoxib were prepared by direct compression method using Hibiscus rosasinesis leaves mucilage as natural super disintegrant with a view to enhance patient compliance and to avoid hepatic first pass metabolism and to improve its bioavailability. The prepared batches of tablets were evaluated for hardness, friability, drug content uniformity, wetting time, water-absorption ratio and in-vitro dispersion time. Addition of Drug: β-cyclodextrin inclusion complex leads to improve the dissolution characteristics and solubility of drug at optimum concentration (1:5). It was found that the formulation F5 was found to be optimized formulation from the data obtained. It is observed from the formulation F5 which shown disintegration time 30±1.25 sec. and percentage cumulative drug release shown 95.84±2.08 within 30 minute. The best formulations F5 was analyzed for short-term stability studies on the promising formulation indicated that there are no significant changes in drug content and in vitro dispersion time. The formulation was found to be stable.

Keyword

Orodispersible tablets, Etoricoxib, Natural super disintergrant, Rheumatoid arthritis, Inclusion complex, In-vitro drug release

References

[1] SunidhiMahant, ShivaliSingla, Sachin Goyal, Bhimi Kumari. (2017). Abhishek Soni Formulation and Evaluation of Mouth Dissolving Tablets of Ondansetron Hydrochloride Using Plantago ovata (Isapghula) Mucilage as Natural Super Disintegrating Agent. International Journal of Pharmaceutical Sciences and Drug Research, 2017, 9(5): 240-246.

[2] RajniBala, ReechaMadaan, Vibhu, Aneesh, and Dr. Sandeep Arora. Isolation and Evaluation of Hibiscus Rosa- Sinensis Leaf Mucilage as Superdisintegrant. European Journal of Pharmaceutical And Medical Research ejpmr, 2016, 3(8), 434-440.

[3] https://en.m.wikipedia.org/wiki/Etoricoxib. 

[4] https://pubchem.ncbi.nlm.nih.gov/compound/Etoricoxib#sectionComputed Properties. 

[5] https://www.medicineindia.org/pharmacology-for-generic/208/etoricoxib.

[6] K. Srinivasarav. (2017). An Overview on Preformulation for Pharmaceutical Product Development and Drug Excipient In-compatibility Studies. International Journal of Pharma and Chemical Research. I Volume 3 I Issue 2 I Apr-Jun I 2017(5.1.A).

[7] Shivani Kala and Divya Juyal. (2016). Preformulation and characterization studies of aceclofenac active ingredient. The Pharma Innovation Journal, 2016; 5(9): 110-119 (5.1.B).

[8] B. P. Patel, J. K. Patel, G. C. Rajput, and R. S. Thakor. Formulation and Evaluation of Mouth Dissolving Tablets of Cinnarizine Indian Journal of Pharmaceutical Sciences July-August.

[9] Chowdaryk, P. R., K. Surya Prakasa Rao, and•Amar Ayireddy. Formulation and evaluation of etoricoxib solid dispersions em-ploying starch phosphate, pvp and peg 4000 – a factorial study Asian journal of pharmaceutical and clinical research, vol. 4, suppl, 2, 2011 (5.1.D).

[10] Shivani Kala and Divya Juyal. Preformulation and characterization studies of aceclofenac active ingredient. The Pharma Inno-vation Journal, 2016, 5(9): 110-119.  

[11] Gupta Ashish, Bhadoria Juhi, Darwhekar, G. N. (2019). Formulation and Evaluation of Orodispersible Tablet of Atorvastatin Calcium by Using Hibiscus rosasinesis Mucilage as Natural Superdisintegrant. Journal of Drug Delivery & Therapeutics, 2019, 9(6): 90-94.

[12] Shivani Kala and Divya Juyal. (2016). Preformulation and characterization studies of aceclofenac active ingredient. The Pharma Innovation Journal, 2016, 5(9): 110-119.  

[13] K. Srinivasarav. (2017). An Overview on Preformulation for Pharmaceutical Product Development and Drug Excipient In-compatibility Studies. International Journal of Pharma And Chemical Research, I Volume 3 I Issue 2 I Apr-Jun I 2017(5.1.A).

[14] Shivani Kala and Divya Juyal. (2016). Preformulation and characterization studies of aceclofenac active ingredient. The Pharma Innovation Journal, 2016, 5(9): 110-119 (5.1.B).

[15] Liberman, H. A., Lachmann, L., and Shwartz, J. B. Pharmaceutical Dosage Forms: Tablets. Vol. 1, 2nd ed, Marcel Dekker Inc., USA; 285-327.

[16] Gupta Ashish, Bhadoria Juhi, Darwhekar, G. N. (2019). Formulation and Evaluation of Orodispersible Tablet of Atorvastatin Calcium by Using Hibiscus rosasinesis Mucilage as Natural Superdisintegrant. Journal of Drug Delivery & Therapeutics, 2019; 9(6): 90-94.

Copyright

© 2022 by the author(s).
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial-NoDerivatives (CC BY-NC-ND) license, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited and is not modified or adapted.
https://creativecommons.org/licenses/by-nc-nd/4.0/

How to cite this paper

Formulation and Evaluation of Orodispersible Tablets of Etoricoxib Using Hibiscus Rosa Sinesis Muscillage as Natural Super Disintegrant

How to cite this paper: Sandeep Patel, Komal Tikariya, Jayanti Mukherjee. (2022) Formulation and Evaluation of Orodispersible Tablets of Etoricoxib Using Hibiscus Rosa Sinesis Muscillage as Natural Super Disintegrant. International Journal of Clinical and Experimental Medicine Research6(3), 222-231.

DOI: http://dx.doi.org/10.26855/ijcemr.2022.07.002